The Nontuberculous Mycobacterial Infections pipeline report provides detailed information of the Nontuberculous Mycobacterial Infections pipeline products from the initial phase of product development until its commercialisation in the Nontuberculous Mycobacterial Infections market.

Nontuberculous Mycobacterial Infections Pipeline Drugs Report

DelveInsight&rsquo;s, &ldquo;Nontuberculous Mycobacteria Infections - Pipeline Insight, 2025,&rdquo; report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Nontuberculous Mycobacteria Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.&nbsp;
<h2>Geography Covered</h2>
<ul>
<li>Global coverage</li>
</ul>
<h2>Nontuberculous Mycobacteria Infections Understanding</h2>
Nontuberculous Mycobacteria Infections: Overview
Nontuberculous Mycobacterial (NTM) infections are caused by mycobacteria that are not part of the Mycobacterium tuberculosis complex or Mycobacterium leprae. These organisms are ubiquitous in the environment, found in soil, water, and dust, and they can cause a wide range of infections, particularly in individuals with compromised immune systems or pre-existing lung conditions. NTM infections are becoming increasingly recognized as a significant health concern, particularly in developed countries.
&nbsp;
The symptoms of NTM infections vary depending on the site of infection but commonly include chronic cough, fatigue, weight loss, and hemoptysis (coughing up blood) when the lungs are involved. Other potential symptoms include lymphadenitis (swollen lymph nodes), skin lesions, and soft tissue abscesses. Pulmonary NTM infections are the most common, especially among individuals with chronic lung diseases like chronic obstructive pulmonary disease (COPD), bronchiectasis, or cystic fibrosis.
&nbsp;
NTM infections occur when these bacteria are inhaled or enter through broken skin, but unlike tuberculosis, they are not usually spread from person to person. The pathophysiology involves the mycobacteria entering the host and evading the immune system, leading to persistent infection. NTM organisms can form biofilms and persist in macrophages, making them difficult to eradicate. The risk of infection increases in people with weakened immune systems, such as those with HIV/AIDS, or individuals on immunosuppressive therapies.
&nbsp;
Diagnosis of NTM infections involves a combination of clinical, radiological, and microbiological assessments. Clinical suspicion is raised based on symptoms and risk factors. Imaging, such as chest X-rays or CT scans, may show characteristic findings like nodules, bronchiectasis, or cavitary lesions. Definitive diagnosis is made by isolating the NTM organism from sputum or other body fluids/tissues through cultures. Molecular methods, like PCR, can also be used for species identification.
&nbsp;
Treatment of NTM infections is challenging and often requires prolonged antibiotic therapy, typically spanning 12 months or more. The choice of antibiotics depends on the specific NTM species and the patient's overall health. Commonly used antibiotics include macrolides (such as clarithromycin or azithromycin), rifamycins (such as rifampin), and ethambutol. In some cases, surgical intervention may be necessary to remove infected tissue. Managing NTM infections also involves addressing underlying conditions and improving immune function to enhance the chances of successful treatment.&nbsp;
&nbsp;
"Nontuberculous Mycobacteria Infections - Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nontuberculous Mycobacteria (NTM) Infections pipeline landscape is provided which includes the disease overview and Nontuberculous Mycobacteria Infections treatment guidelines. The assessment part of the report embraces, in depth Nontuberculous Mycobacteria Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nontuberculous Mycobacteria Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
<h2>Report Highlights</h2>
The companies and academics are working to assess challenges and seek opportunities that could influence Nontuberculous Mycobacteria Infections R&amp;D. The therapies under development are focused on novel approaches to treat/improve Nontuberculous Mycobacteria Infections.
<h2>Nontuberculous Mycobacteria Infections Emerging Drugs Chapters</h2>
This segment of the Nontuberculous Mycobacteria Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
&nbsp;
Nontuberculous Mycobacteria Infections Emerging Drugs
&nbsp;
MNKD-101: Mannkind Corporation
MNKD-101 (Clofazimine) is being developed as an inhalation treatment option for nontuberculous mycobacterial (NTM) lung disease. NTM lung disease is a serious infection that is caused by bacteria common in the environment that can lead to a reduction in lung function, cough, fatigue, and quality of life. It is estimated that approximately 86,000 people in the U.S. are living with NTM lung disease. MNKD-101 has been designated by the FDA as both an orphan lung and a qualified infectious disease product (QIDP) for the treatment of pulmonary NTM infections. U.S. Food and Drug Administration (FDA) has granted Fast Track designation of Clofazimine Inhalation Suspension (MNKD-101) for the treatment of nontuberculous mycobacterial (NTM) lung disease. Currently, the drug is in Phase III stage of its development for the treatment of Nontuberculous Mycobacterial Infections.
&nbsp;
MAT2501: Matinas BioPharma
MAT2501 is an orally-administered Lipid Nano-Crystal formulation of the gram-negative antibiotic agent, amikacin. The drug is in Phase I clinical development for the treatment of Nontuberculous Mycobacteria (NTM) Infections. As a broad-spectrum aminoglycoside, amikacin is highly effective in treating a range of chronic and acute bacterial infections, including Non-Tuberculous Mycobacterium (NTM) infections. FDA designated MAT2501 as a QIDP and Orphan Drug for the treatment of NTM infections. Currently, the drug is in Phase I stage of its development for the treatment of Nontuberculous Mycobacterial Infections.
Further product details are provided in the report&hellip;&hellip;..
<h2>Nontuberculous Mycobacteria Infections: Therapeutic Assessment</h2>
This segment of the report provides insights about the different Nontuberculous Mycobacteria (NTM) Infections drugs segregated based on following parameters that define the scope of the report, such as:
&nbsp;
Major&nbsp;Players in Nontuberculous Mycobacteria Infections
There are approx. 10+ key companies which are developing the therapies for Nontuberculous Mycobacteria Infections. The companies which have their Nontuberculous Mycobacteria Infections drug candidates in the most advanced stage, i.e. Phase III include, Mannkind Corporation.
&nbsp;
Phases
DelveInsight&rsquo;s report covers around 10+ products under different phases of clinical development like
<ul>
<li>Late stage products (Phase III)</li>
<li>Mid-stage products (Phase II)</li>
<li>Early-stage product (Phase I) along with the details of</li>
<li>Pre-clinical and Discovery stage candidates</li>
<li>Discontinued &amp; Inactive candidates</li>
</ul>
&nbsp;
Route of Administration
Nontuberculous Mycobacteria Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
<ul>
<li>Oral</li>
<li>Parenteral</li>
<li>Intravitreal</li>
<li>Subretinal</li>
<li>Topical</li>
</ul>
&nbsp;
Molecule Type
Products have been categorized under various Molecule types such as
<ul>
<li>Recombinant fusion proteins</li>
<li>Small molecule</li>
<li>Monoclonal antibody</li>
<li>Peptide</li>
<li>Polymer&nbsp;</li>
<li>Gene therapy</li>
</ul>
&nbsp;
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
<h2>Nontuberculous Mycobacteria Infections: Pipeline Development Activities</h2>
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nontuberculous Mycobacteria (NTM) Infections therapeutic drugs key players involved in developing key drugs.
&nbsp;
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nontuberculous Mycobacteria (NTM) Infections drugs.
<p style="background-color: #ffffff; box-sizing: border-box; margin: 0px 0px 1rem; padding: 0px; letter-spacing: 0.02em; color: #303030; font-family: Lato, sans-serif; line-height: 1.4; text-rendering: optimizelegibility; text-align: justify; font-size: 14px !important;">Visit to learn about the key factors, trends, innovations, and developments driving the market growth, at:&nbsp;<a href="../../report-store/nontuberculous-mycobacterial-ntm-infections-market">Nontuberculous Mycobacterial (NTM) Infections Market</a>
<h2>Nontuberculous Mycobacteria Infections Report Insights</h2>
<ul>
<li>Nontuberculous Mycobacteria Infections Pipeline Analysis</li>
<li>Therapeutic Assessment</li>
<li>Unmet Needs</li>
<li>Impact of Drugs</li>
</ul>
<h2>Nontuberculous Mycobacteria Infections Report Assessment</h2>
<ul>
<li>Pipeline Product Profiles</li>
<li>Therapeutic Assessment</li>
<li>Pipeline Assessment</li>
<li>Inactive drugs assessment</li>
<li>Unmet Needs</li>
</ul>
<h2>Key Questions</h2>
Current Treatment Scenario and Emerging Therapies:
<ul>
<li>How many companies are developing Nontuberculous Mycobacteria Infections drugs?</li>
<li>How many Nontuberculous Mycobacteria Infections drugs are developed by each company?</li>
<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nontuberculous Mycobacteria Infections?</li>
<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Nontuberculous Mycobacteria Infections therapeutics?</li>
<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?</li>
<li>What are the clinical studies going on for Nontuberculous Mycobacteria Infections and their status?</li>
<li>What are the key designations that have been granted to the emerging drugs?</li>
</ul>

Introduction
Executive Summary
Nontuberculous Mycobacteria Infections: Overview
<ul>
<li>Causes</li>
<li>Mechanism of Action&nbsp;</li>
<li>Signs and Symptoms</li>
<li>Diagnosis</li>
<li>Disease Management</li>
</ul>
Pipeline Therapeutics
<ul>
<li>Comparative Analysis</li>
</ul>
Therapeutic Assessment
<ul>
<li>Assessment by Product Type</li>
<li>Assessment by Stage and Product Type</li>
<li>Assessment by Route of Administration</li>
<li>Assessment by Stage and Route of Administration</li>
<li>Assessment by Molecule Type</li>
<li>Assessment by Stage and Molecule Type&nbsp;</li>
</ul>
Nontuberculous Mycobacteria Infections &ndash; DelveInsight&rsquo;s Analytical Perspective
In-depth Commercial Assessment
<ul>
<li>Nontuberculous Mycobacteria Infections companies&rsquo; collaborations, Licensing, Acquisition -Deal Value Trends</li>
</ul>
Nontuberculous Mycobacteria Infections Collaboration Deals
<ul>
<li>Company-Company Collaborations (Licensing / Partnering) Analysis</li>
<li>Company-University Collaborations (Licensing / Partnering) Analysis</li>
</ul>
Late Stage Products (Phase III)
<ul>
<li>Comparative Analysis</li>
</ul>
MNKD-101: Mannkind Corporation
<ul>
<li>Product Description</li>
<li>Research and Development&nbsp;</li>
<li>Product Development Activities&nbsp;</li>
</ul>
Drug profiles in the detailed report&hellip;..
Mid Stage Products (Phase II)
<ul>
<li>Comparative Analysis</li>
</ul>
Drug Name: Company Name
<ul>
<li>Product Description</li>
<li>Research and Development&nbsp;</li>
<li>Product Development Activities&nbsp;</li>
</ul>
Drug profiles in the detailed report&hellip;..
Early Stage Products (Phase I)&nbsp;
<ul>
<li>Comparative Analysis</li>
</ul>
MAT2501: Matinas BioPharma
<ul>
<li>Product Description</li>
<li>Research and Development&nbsp;</li>
<li>Product Development Activities&nbsp;</li>
</ul>
Drug profiles in the detailed report&hellip;..
Preclinical and Discovery Stage Products
<ul>
<li>Comparative Analysis</li>
</ul>
Drug Name: Company Name
<ul>
<li>Product Description</li>
<li>Research and Development&nbsp;</li>
<li>Product Development Activities&nbsp;</li>
</ul>
Drug profiles in the detailed report&hellip;..
Inactive Products
<ul>
<li>Comparative Analysis</li>
</ul>
Nontuberculous Mycobacteria Infections Key Companies
Nontuberculous Mycobacteria Infections Key Products
Nontuberculous Mycobacteria Infections- Unmet Needs
Nontuberculous Mycobacteria Infections- Market Drivers and Barriers
Nontuberculous Mycobacteria Infections- Future Perspectives and Conclusion
Nontuberculous Mycobacteria Infections Analyst Views
Nontuberculous Mycobacteria Infections Key Companies
Appendix

Nontuberculous Mycobacterial Infections - Pipeline Insight, 2025

Nontuberculous Mycobacterial Infections Pipeline Insights, 2025 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across